New hope for drug-resistant lung cancer: combo therapy enters trial
NCT ID NCT07548060
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs (Sacituzumab Tirumotecan and Furmonertinib) in 25 people with advanced non-squamous non-small cell lung cancer that has an EGFR gene mutation and has stopped responding to standard treatments. The goal is to see if the combo can shrink tumors or slow disease progression. Participants must have stage IIIB/IV cancer and have already tried EGFR-targeted therapy and platinum chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR GENE MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo outsmart resistant lung cancer?
- Seeing Cancer's hidden markers: a new PET tracer could reveal who responds to targeted therapy
- Lab-Grown lung tumors could reveal why some drugs work and others fail
- New antibody drug targets Cancer-Related fluid in the lungs
- New drug cocktail shows promise for Hard-to-Treat lung cancer
- New combo shrinks lung tumors before surgery in early trial